Immune Response in the SAPHO Syndrome

SAPHO Syndrome Clinical Trial

Official title:

Immune Mechanisms During SAPHO Syndrome and Treatment by Etarnecept

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01688219
• Other study ID #: 45896566645469
• Status: Completed
• Phase: N/A
• First received: September 14, 2012
• Last updated: September 18, 2012
• Start date: November 2005
• Est. completion date: May 2008

Study information

• Verified date: October 2007
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The aetiology of SAPHO syndrome seems to involve genetic, infectious and immunological components. The investigators examined innate and adaptative immune responses in SAPHO syndrome as compared with psoriatic arthritis and rheumatoid arthritis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: May 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 1 Year to 70 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of SAPHO syndrome

• Must have bone lesions

Exclusion Criteria:

• Infliximab treatment

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• SAPHO Syndrome
• Syndrome

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IL-8 production by PMN		24 h	No
Secondary	TNFalpha production by PMN		24 h	No